Ginkgo Bioworks Holdings Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
19. Net Loss per Share
- Net Loss per Share
The Company computes net loss per share of Class A common stock and Class B common stock using the two-class method required for participating securities. The earnings per share amounts are the same for the different classes of common stock because the holders of each class are legally entitled to equal per share distributions whether through dividends or liquidation. The calculation of basic and diluted earnings per common share is as follows (in thousands, except per share amounts):
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Numerator: | |||
| Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders, basic | $(892,869) | $(2,104,929) | $(1,830,047) |
| Less: change in fair value of warrant liabilities | — | — | 58,615 |
| Less: change in fair value of contingent consideration common shares liability | — | 3,143 | — |
| Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders, diluted | $(892,869) | $(2,108,072) | $(1,888,662) |
| Denominator | |||
| Weighted average common shares outstanding, basic | 1,944,420 | 1,679,061 | 1,359,849 |
| Effect of dilutive securities: | |||
| Warrants | — | — | 525 |
| Contingent consideration common shares | — | 777 | — |
| Weighted average common shares outstanding, diluted | 1,944,420 | 1,679,839 | 1,360,373 |
| Basic net loss per share | $(0.46) | $(1.25) | $(1.35) |
| Diluted net loss per share | $(0.46) | $(1.25) | $(1.39) |
The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive (in thousands):
| As of December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Unvested RSUs | 152,168 | 134,436 | 168,322 |
| Ginkgo and Sponsor earnout shares (1) | 152,122 | 156,781 | 160,995 |
| Warrants to purchase Class A common stock | 51,825 | 51,825 | — |
| Outstanding stock options | 7,688 | 12,711 | 25,229 |
| Unvested RSAs | — | 4 | 183 |
| 363,803 | 355,757 | 354,729 | |
(1)Represents earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.